Winnie Hua
Overview
Explore the profile of Winnie Hua including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
79
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, et al.
Lancet Oncol
. 2024 Jun;
25(8):1003-1014.
PMID: 38889735
Background: CASSIOPEIA part 1 demonstrated superior depth of response and prolonged progression-free survival with daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) versus bortezomib, thalidomide, and dexamethasone (VTd) alone...
2.
Pappas D, Shan Y, Lesperance T, Kricorian G, Karis E, Rebello S, et al.
ACR Open Rheumatol
. 2020 Sep;
2(10):588-594.
PMID: 32990361
Objective: The purpose of this study was to evaluate maintenance of remission/low disease activity (LDA) in patients with rheumatoid arthritis (RA) who achieved remission/LDA with etanercept (ETN) plus a conventional...
3.
Pappas D, Litman H, Lesperance T, Kricorian G, Karis E, Rebello S, et al.
Rheumatol Int
. 2020 Sep;
41(2):381-390.
PMID: 32876744
Biological disease-modifying antirheumatic drugs (bDMARDs) monotherapy may enhance adherence and decrease adverse events compared to combination therapy with conventional synthetic DMARDs (csDMARDs); however, persistence with bDMARD monotherapy has not been...
4.
Mease P, Liu M, Rebello S, Hua W, McLean R, Yi E, et al.
ACR Open Rheumatol
. 2020 Jul;
2(7):449-456.
PMID: 32627974
Objective: To compare the characteristics of patients with axial spondyloarthritis (axSpA) who had enthesitis versus those without enthesitis. Methods: This study included adult patients with axSpA enrolled in the Corrona...
5.
Mease P, Liu M, Rebello S, Hua W, McLean R, Hur P, et al.
J Rheumatol
. 2020 Jun;
48(3):367-375.
PMID: 32482647
Objective: To assess the effect of clinical enthesitis by body site in patients with psoriatic arthritis (PsA). Methods: Adults with PsA enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry (March 2013-March...
6.
Harrold L, Litman H, Connolly S, Alemao E, Kelly S, Rebello S, et al.
Rheumatol Ther
. 2019 Mar;
6(2):217-230.
PMID: 30868550
Introduction: Anti-citrullinated protein antibodies (ACPAs) are highly specific serological biomarkers that are indicative of a poor prognosis in patients with rheumatoid arthritis (RA). The effectiveness of biologic disease-modifying antirheumatic drugs...
7.
Alemao E, Litman H, Connolly S, Kelly S, Hua W, Rosenblatt L, et al.
J Rheumatol
. 2018 Jul;
45(10):1353-1360.
PMID: 29961696
Objective: To characterize patients with rheumatoid arthritis (RA) by number of poor prognostic factors (PPF: functional limitation, extraarticular disease, seropositivity, erosions) and evaluate treatment acceleration, clinical outcomes, and work status...
8.
Harrold L, Litman H, Connolly S, Kelly S, Hua W, Alemao E, et al.
J Rheumatol
. 2017 Nov;
45(1):32-39.
PMID: 29093151
Objective: Assess whether baseline anticyclic citrullinated peptide antibodies (anti-CCP) status is associated with treatment response in patients with rheumatoid arthritis (RA) initiating abatacept (ABA) or a tumor necrosis factor-α inhibitor...
9.
Harrold L, Litman H, Connolly S, Kelly S, Hua W, Alemao E, et al.
Clin Rheumatol
. 2017 Mar;
36(6):1215-1220.
PMID: 28251392
The objective of the study was to examine whether disease duration independently predicts treatment response among biologic-naïve patients with rheumatoid arthritis (RA) initiating abatacept in clinical practice. Using the Corrona...